Identification of genes and pathways, including the CXCL2 axis, altered by DNA methylation in hepatocellular carcinoma
- 18 December 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 145 (3), 675-684
- https://doi.org/10.1007/s00432-018-2824-0
Abstract
Purpose Recent genetic studies have suggested that tumor suppressor genes are often silenced during carcinogenesis via epigenetic modification caused by methylation of promoter CpG islands. Here, we characterized genes inactivated by DNA methylation in human hepatocellular carcinoma (HCC) to identify the genes and pathways involved in DNA methylation in hepatocellular carcinoma. Methods Eight HCC-derived cell lines were treated with a DNA demethylating agent, 5-aza-2′-deoxycytidine. Additionally, 100 pairs of primary HCC and adjacent non-cancerous tissues as well as 15 normal liver tissues were analyzed by comprehensive gene expression analysis using microarrays. Moreover, gene set enrichment analysis identified the major molecular pathways associated with DNA methylation. Validation of gene expression and DNA methylation status was performed by real-time PCR after bisulfite modification. Results We showed that CXCL2, an immune-related chemokine, expression was significantly downregulated in tumor tissues and also significantly upregulated by DAC treatment in cell lines. Furthermore, we observed a statistically significant difference in methylation status between normal liver tissues and tumor tissues (P < 0.05). In addition, tumors with higher CXCL2 expression included significantly more numbers of multiple tumors than the lower expression group. Conclusions We identified CXCL2, an immune-related chemokine, decreased in hepatocellular carcinoma and the regulation mechanism may be controlled by methylation. Further studies should be warranted to examine if and to what extent the gene is actually suppressed by methylation and if there is a possibility that the CXCL2 axis plays a role for diagnosis and treatment of hepatocellular carcinoma.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP26870175, 15H04714)
This publication has 30 references indexed in Scilit:
- The hypoxic environment reprograms the cytokine/chemokine expression profile of human mature dendritic cellsImmunobiology, 2013
- JunB contributes to Id2 repression and the epithelial–mesenchymal transition in response to transforming growth factor–βThe Journal of cell biology, 2012
- CXC Chemokine Ligand 2 Induced by Receptor Activator of NF-κB Ligand Enhances OsteoclastogenesisThe Journal of Immunology, 2010
- Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survivalInternational Journal of Colorectal Disease, 2010
- Epigenetics in CancerNew England Journal of Medicine, 2008
- Mullerian-Inhibiting Substance Induces Gro-β Expression in Breast Cancer Cells through a Nuclear Factor-κB–Dependent and Smad1-Dependent MechanismCancer Research, 2007
- Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4Nature, 2006
- Gene expression profiles of different clinical stages of colorectal carcinoma: toward a molecular genetic understanding of tumor progressionInternational Journal of Colorectal Disease, 2005
- Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.Proceedings of the National Academy of Sciences of the United States of America, 1996
- Normal breast epithelial cells produce interleukins 6 and 8 together with tumor‐necrosis factor: Defective il6 expression in mammary carcinomaInternational Journal of Cancer, 1993